(Q43030170)

English

Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response

scientific article published in January 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

0 references

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Westin J

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Lindh M

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Nenonen N

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Norkrans G

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Wejstål R

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 January 2001

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

110-115

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients.

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemiological applications

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Loss of serum HCV RNA at week 4 of interferon‐α therapy is associated with more favorable long‐term response in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Factors useful in predicting the response to interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1080%2F003655401750065481

21 January 2018

Identifiers

10.1080/003655401750065481

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43030170&oldid=1977634105"